1. Narayana Holla
  2. Gestion du programme
  3. lundi 25 décembre 2017
  4.  S'abonner via e-mail

Dear TechNet viewers

We wish you all a merry Christmas and happy new year to come.

We wish to share the attached PPT on anti rabies vaccine administration presented in the integrated teaching session to the PGs & Faculties of departments of KVG Medical College.

The ppt is free for editing for further fine tuning.

As a routine Academic activity, I was asked to make a presentation on ARV administration. As we strongly believe in learning before teaching, learn by working together, learn while teaching; we visited the injection room where ARV is administered to the needy patients. We got very good opportunity to learn very crucial aspects.

The planning unit is supplied with Abhayrab and equine Rabies Immuno-Globulin (eRIG) by the Government which is free for the Below Poverty Line (BPL) patients and chargeable for the Above Poverty Line (APL) patients as per norms acceptable to the community.

ARV is administered through Intra-Dermal (ID) route as a routine policy: 0.1mL at 2 sites to the 2 upper arms. Nurses who are routinely administering the vaccine have the required skill but we found gap in the junior doctors regarding how much vaccine to draw using insulin syringe, proper I.D administration – too small a weal developed as vaccine got lodged subcutaneously. In one of the planning units with very few patient loads, staff revealed that the reconstituted vial was used till the last 0.1mL was administered, often for more than a week though kept in the cold chain and away from light but no vaccinees died sofar probably the dogs were non rabid.

In view of this, we strongly recommend regular training and reorientation of treating Doctors on managing animal bites including administration of  TT, providing appropriate antibiotic, analgesics, assurance / counseling apart from specific ARV with or without RIG.

Best wishes

Holla n Team

Pièces jointes


Il n’y a encore aucune réponse faite pour cette discussion.
Cependant, vous n'êtes pas autorisé à répondre à ce message.